Casdin Capital 13F holdings, Q2 2018
Holdings as of June 30, 2018 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 32 US equity positions worth $708.7m in its Q2 2018 13F filing. The largest position was FOUNDATION MEDICINE INC at 13.2% of the reported book, followed by LOXO ONCOLOGY INC and 2655787D. Against the Q1 2018 filing, it opened 4 new positions, added to 10 and reduced 4 among the top 32 holdings.
What did Casdin Capital own in Q2 2018? Top 32 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2018 |
|---|---|---|---|---|---|---|---|
| 1 | FOUNDATION MEDICINE INC | 13.2% | $93.6m | 685,000 | 32% | added | |
| 2 | LOXO ONCOLOGY INC | 8.8% | $62.5m | 360,000 | 0% | held | |
| 3 | 2655787D BLUEPRINT MEDICINES CORP | 5.7% | $40.3m | 635,000 | 82% | added | |
| 4 | SG7 SAGE THERAPEUTICS INC | 5.5% | $39.1m | 250,000 | 0% | held | |
| 5 | MYOKARDIA INC | 5.5% | $38.7m | 780,000 | 39% | added | |
| 6 | SPARK THERAPEUTICS INC | 5.4% | $38.3m | 463,000 | 0% | held | |
| 7 | BLUEBIRD BIO INC | 4.4% | $31.4m | 200,000 | 38% | added | |
| 8 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 4.3% | $30.7m | 364,776 | 0% | held |
| 9 | FATE FATE THERAPEUTICS INC | Healthcare | 4.2% | $29.5m | 2,600,000 | 0% | held |
| 10 | CDXS CODEXIS INC | Healthcare | 4.1% | $29.2m | 2,025,000 | 0% | held |
| 11 | MAGENTA THERAPEUTICS INC | 3.9% | $27.5m | 2,035,818 | – | new | |
| 12 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.8% | $26.6m | 270,000 | 8% | added |
| 13 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 3.1% | $22.2m | 1,135,000 | 0% | held |
| 14 | GLOBAL BLOOD THERAPEUTICS IN | 3.1% | $21.7m | 480,000 | -20% | reduced | |
| 15 | GNMK GENMARK DIAGNOSTICS INC | 3.1% | $21.7m | 3,400,000 | -12% | reduced | |
| 16 | ILMN ILLUMINA INC | Healthcare | 2.8% | $20.0m | 71,500 | 0% | held |
| 17 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 2.8% | $19.9m | 1,400,000 | 0% | held |
| 18 | AUDENTES THERAPEUTICS INC | 2.4% | $17.2m | 450,000 | 0% | held | |
| 19 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.8% | $12.9m | 220,000 | 63% | added |
| 20 | EVH EVOLENT HEALTH INC | Healthcare | 1.6% | $11.6m | 550,000 | -50% | reduced |
| 21 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 1.6% | $11.4m | 1,000,000 | – | new |
| 22 | ONC BEIGENE LTD | Healthcare | 1.5% | $10.8m | 70,000 | 0% | held |
| 23 | OSUR ORASURE TECHNOLOGIES INC | Healthcare | 1.5% | $10.5m | 640,000 | 167% | added |
| 24 | CLOVIS ONCOLOGY INC | 1.4% | $10.0m | 220,000 | 24% | added | |
| 25 | EDIT EDITAS MEDICINE INC | Healthcare | 0.9% | $6.4m | 178,333 | 34% | added |
| 26 | NEOG NEOGEN CORP | Healthcare | 0.7% | $5.2m | 65,000 | 0% | held |
| 27 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.7% | $4.7m | 207,500 | 0% | held |
| 28 | NEON THERAPEUTICS INC | 0.6% | $4.3m | 338,345 | – | new | |
| 29 | ZLAB ZAI LAB LTD | Healthcare | 0.4% | $3.1m | 135,000 | 0% | held |
| 30 | JOUNCE THERAPEUTICS INC | 0.4% | $2.9m | 375,000 | -41% | reduced | |
| 31 | CDNA CAREDX INC | Healthcare | 0.3% | $2.4m | 200,000 | – | new |
| 32 | HOMOLOGY MEDICINES INC | 0.3% | $2.3m | 115,000 | 92% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.